Valneva’s Chikungunya Vaccine: UK Limits Use to Over-60s | Stock Impact

Updated recommendations regarding the chikungunya vaccine IXCHIQ® from the UK’s regulatory authorities could have a short-term impact on Valneva’s (VALN) revenue, but a complete halt in sales is not anticipated. The vaccine remains positively assessed for individuals aged 18 to 59 at risk of infection. Long-term effects will depend on additional safety data and approvals in other regions, requiring continued monitoring of the situation.

On February 13, Valneva announced that the UK’s Commission on Human Medicines (CHM) had updated its guidance for the use of its chikungunya vaccine, IXCHIQ®. The new recommendations include restricting use in individuals aged 60 and over, those with certain underlying health conditions, and limiting the timing of vaccination relative to travel plans.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) confirmed that the benefit-risk profile of IXCHIQ® remains positive for those aged 18 to 59 who are at risk of chikungunya infection. This update follows a temporary suspension by the MHRA after reports of serious adverse events in older adults during a vaccination campaign on Réunion Island in France.

Valneva stated its commitment to maintaining the highest safety standards and will continue to monitor post-market safety data for IXCHIQ® and collaborate with relevant authorities to take further action if needed. This commitment is crucial as chikungunya is a debilitating disease that can cause long-term pain and significant economic and healthcare burdens.

Chikungunya virus is spread by Aedes mosquitoes and causes fever and severe joint pain upon infection. The World Health Organization (WHO) identifies the virus as a major public health threat, with mosquito habitats expanding due to climate change.

Valneva is a specialist vaccine company focused on the prevention of infectious diseases. Beyond IXCHIQ®, the company is also collaborating with Pfizer on a Lyme disease vaccine, among other innovative vaccine candidates. This diverse pipeline highlights the company’s dedication to addressing unmet needs in infectious disease prevention.

Analysts predict substantial growth for Valneva, forecasting revenue to increase from $225.43 million in 2026 to $425.29 million in 2027, with the potential for earnings per share to turn positive in 2027. These projections suggest a promising future for the company, contingent on navigating the current regulatory challenges and securing further approvals.

&lt. ⓒ초이스스탁 AI 투자속보 ‘애드가플래시’ – 무단전재 & 재배포 금지 >